[Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organasation «Association of Ophthalmologists»].
V V NeroyevYu S AstakhovS A KorotkihE V BobykinO V ZaytsevaA B LisochkinaA F BrovkinaMaria BudzinskayaM V GatsuN N GrigoryevaA S IzmaylovE V KarlovaM A KovalevskayaP A NechiporenkoI E PanovaA A RyabtsevaS V SimonovaS N TultsevaAnzhela Zh FursovaF E ShadrichevM M ShishkinM P KharlampidiPublished in: Vestnik oftalmologii (2020)
Intravitreal drug administration is a procedure that has become widespread in modern ophthalmology. However, there is no global consensus on certain aspects of this manipulation, and practitioners feel the need for guidelines. In the Russian Federation, until now, such a document was not available. The expert council on diseases of the retina and optic nerve of All-Russian public organization «Association of Ophthalmologists», with participation of invited specialists, has studied and analyzed the existing foreign guidelines for performing intravitreal injections, as well as the regulatory framework in Russia. As a result, this Protocol was developed and approved for use in the healthcare system of the Russian Federation. The document regulates the requirements for specialists and organizations, the conditions for performing the procedure and the necessary material resources and presents an algorithm for performing intravitreal drug administration, a patient examination check-list for various conditions of the procedure, as well as parameters for evaluating and monitoring the quality of the procedure.
Keyphrases
- optic nerve
- drug administration
- clinical practice
- vascular endothelial growth factor
- diabetic retinopathy
- optical coherence tomography
- age related macular degeneration
- minimally invasive
- drug delivery
- healthcare
- randomized controlled trial
- mental health
- primary care
- machine learning
- emergency department
- physical activity
- endothelial cells
- transcription factor
- case report
- adverse drug